Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
Public ClinicalTrials.gov record NCT01931566. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone compared with placebo to delay the onset of MCI-AD in cognitively-normal participants who are at high-risk for developing MCI within 5 years.
Study identification
- NCT ID
- NCT01931566
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 3,494 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 65 Years to 83 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 1, 2013 (Actual)
- Primary completion
- Jul 24, 2018 (Actual)
- Completion
- Sep 6, 2018 (Actual)
- Last update posted
- Sep 16, 2019
2013 – 2018
United States locations
- U.S. sites
- 34
- U.S. states
- 19
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Sun City | Arizona | — | — |
| Not listed | Long Beach | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | San Francisco | California | — | — |
| Not listed | Delray Beach | Florida | — | — |
| Not listed | Fort Myers | Florida | — | — |
| Not listed | Lady Lake | Florida | — | — |
| Not listed | Lake Worth | Florida | — | — |
| Not listed | Merritt Island | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Port Orange | Florida | — | — |
| Not listed | St. Petersburg | Florida | — | — |
| Not listed | Weston | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Decatur | Georgia | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Elk Grove | Illinois | — | — |
| Not listed | Elk Grove Village | Illinois | — | — |
| Not listed | Iowa City | Iowa | — | — |
| Not listed | Farmington Hills | Michigan | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | Marlton | New Jersey | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Concord | North Carolina | — | — |
| Not listed | Durham | North Carolina | — | — |
| Not listed | Akron | Ohio | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Cordova | Tennessee | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Middleton | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01931566, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 16, 2019 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01931566 live on ClinicalTrials.gov.